ArticleWorld journal of gastroenterology2025
Clinical utility of telomeres as diagnostic and short-term prognostic markers in loco-regional treatment of hepatocellular carcinoma.
Article in World journal of gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHepatocellular carcinoma (HCC) is the most common primary liver cancer, with high mortality at advanced stages. Loco-regional treatment including: Radiofrequency (RF) or transarterial chemoembolization (TACE) is decided according to the size, and the site of the tumor, according to practice guidelines. Alpha fetoprotein (AFP), the most used biomarker in the guidelines, although specific, lacks sensitivity. New biomarkers are needed to understand the underlying pathophysiology, and to be used in clinical practice.
aimTo study the effect of loco-regional treatment on telomere length, as a diagnostic and short-term (3 months) prognostic marker.
methodsThis is a prospective cohort study, and includes 60 patients visiting Ain Shams University Hospitals. The patients were divided into 2 groups: 30 patients with liver cirrhosis (group 1) and 30 HCC patients undergoing RF or TACE (group 2). Laboratory investigations for all patients included: Telomere length in peripheral leukocytes by polymerase chain reaction, AFP, and liver function. In the HCC group, the aforementioned laboratory investigations with abdominal triphasic computed tomography with contrast were performed at baseline, and after 3 months.
resultsWith regard to age, Child-Pugh and Model for End-Stage Liver Disease scores, there was no statistically significant correlation with telomere length. However, there was a correlation between telomere length and age, and both scores before and after 3 months of treatment among HCC patients. On dividing the HCC group according to tumor size with a cutoff of 5 cm, and performing the Mann-Whitney test we found that at baseline telomere length was significantly lower among cases with tumor size ≥ 5 cm than in those with tumor size < 5 cm (30 patients;
conclusionTelomere length in leukocytes is a potential marker in HCC tumor prognosis. Further research using telomerase activity and telomerase reverse transcriptase promoter gene mutation in a larger cohort is recommended.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.